|Day Low/High||3.40 / 3.45|
|52 Wk Low/High||2.25 / 5.40|
Data Further Strengthens Compugen's Rationale for Clinical Development Planand Biomarker Strategy for COM701
The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.
COM902 IND anticipated in 2019 to allow clinical testing of combination therapies with COM701
Multi-year collaboration led by Dr. Miriam Merad
Two poster presentations will present new COM701 and COM902 data
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
Supportive data generated as part of collaboration with the Johns Hopkins University School of Medicine
Presentation will include new data on CGEN-15032, a novel target for cancer immunotherapy
Appointment to take effect October 2, 2017
Current Agreement to continue based on CGEN-15001T
Patent issued by USPTO under pilot program in support of the White House Cancer Moonshot program
Clinical advisory meeting held in preparation for COM701 clinical studies anticipated to begin next year
Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.
When you get an unexpected rally, just go with it, Cramer says.
Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.